Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
09 Oct 2019
In diabetic adults, the presentation of renal disease is heterogenous and involves different mechanisms of action, a new Japan study has found.

Alendronate plus alfacalcidol yields BMD increases in myasthenia gravis patients

08 Jan 2018

Combination therapy with alendronate plus alfacalcidol appears to produce significant increases in bone mineral density (BMD) and reductions in bone turnover biomarker levels, and to lower the rate of hypercalciuria in myasthenia gravis (MG) patients who initiated treatment with glucocorticoids, according to a study.

The open-label study included 75 MG patients who were treated with 0.25 μg of alfacalcidol every other day and 600 mg of calcium daily. Patients with baseline BMD T-score of less than –1.0 received add-on 70 mg of alendronate per week (alendronate group), whereas those with T-score of greater than –1.0 did not (alfacalcidol-alone group).

Results revealed significant improvements in the alendronate group after 12 months of treatment. Specifically, mean BMD increased by 3.4 percent at lumbar spine (p=0.002), by 1.8 percent at femoral neck (p=0.21), and by 2.6 percent in the total hip region (p=0.02).

However, alfacalcidol monotherapy failed to prevent bone loss in MG patients. The mean BMD in the alfacalcidol-alone group decreased by 6.1 percent at lumbar spine, by 3.2 percent at femoral neck, and by 3.3 percent in the total hip region (p<0.001 for all).

In terms of safety, researchers noted a high incidence of hypercalciuria (≥7.5 mmol/24 hour) even after adjusting the dose of alfacalcidol or calcium supplements (40.9 percent in the alendronate group vs 50.9 percent in the alfacalcidol-alone group; p=0.46). At 12 months of treatment, hypercalciuria events were reported in only 10.5 percent in the alendronate group compared with 44.2 percent in the alfacalcidol-alone group.

There were no reports of osteonecrosis of the jaw, atypical fracture, and renal function impairment.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
09 Oct 2019
In diabetic adults, the presentation of renal disease is heterogenous and involves different mechanisms of action, a new Japan study has found.